glp-1 blindness iLIV Clinic | π You've probably seen the headlines: βGLP1 medications can cause blindness!β But here's the fact β¬οΈ β A new JAMA study looked at 275 glp 1 drugs and blindness
Description
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes

Therefore, therapies capable of producing sustained weight reduction may substantially alter disease progression rather than simply treating elevated glucose levels
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist

That vaulted it past Merck ($65.01B), Pfizer ($62.58B), and AbbVie ($61.16B) into the No

Avoiding Abrupt Discontinuation GLP-1 medications should not be stopped abruptly

In this blog, we discuss the benefits of integrating GLP-1 RA medications after bariatric surgery and who should be considered for these medications
